๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Prostate cancer. Primary hormonal treatment

โœ Scribed by L Denis


Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
920 KB
Volume
71
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Regressive changes and neuroendocrine di
โœ Ahlgren, G.; Pedersen, K.; Lundberg, S.; Aus, G.; Hugosson, J.; Abrahamsson, P.- ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 260 KB ๐Ÿ‘ 1 views

## BACKGROUND. We studied the extent of neuroendocrine (NE) tumor cell differentiation and its relation to regressive changes in prostate cancer after 3-month hormonal treatment. METHODS. Radical prostatectomy specimens from 103 patients, randomized to 3-month neoadjuvant LH-RH-analogue treatment (

Treatment failure after primary and salv
โœ Louis L. Pisters ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 42 KB ๐Ÿ‘ 1 views

Salvage radical prostatectomy and salvage cryotherapy are greatly underused as potentially curative treatments in patients with recurrent prostate cancer after initial radiation therapy.

Screening and early hormonal treatment o
โœ Labrie, Fernand ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 201 KB

## Background: I review the data published during the last 5 years on the effects of early treatment of prostate cancer on survival. ## Methods: Data from prospective and randomized studies as well as from population-based studies are presented. ## Results: Two studies (european organization fo

Targeted treatment of prostate cancer
โœ Xinning Wang; Lihong Yin; Pravin Rao; Robert Stein; Kelley M. Harsch; Zhenghong ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 142 KB

## Abstract Over a half century ago, Charles Huggins demonstrated the response of prostate cancer to androgen deprivation therapy. Subsequently, many discoveries and evolving findings continued to support a research rationale focused on the androgen receptor (AR) as a key target for prostate cancer